Patents by Inventor Asim Ray

Asim Ray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8410114
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: April 2, 2013
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lonn, Antonios Nikitidis, Asim Ray
  • Publication number: 20120108610
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lonn, Antonios Nikitidis, Asim Ray
  • Patent number: 8114881
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • Patent number: 7998984
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: August 16, 2011
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Karolina Lawitz, Matti Lepistö, Hans Lönn, Asim Ray
  • Publication number: 20090209555
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: May 7, 2007
    Publication date: August 20, 2009
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • Publication number: 20090131486
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: May 7, 2007
    Publication date: May 21, 2009
    Inventors: Peter Hansen, Karolina Lawitz, Matti Lepisto, Hans Lonn, Asim Ray
  • Publication number: 20060247439
    Abstract: The present invention provides compounds of formula (I), wherein R1 represents a C1-4 alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-4alkyl group; L1 represents an alkylene chain (CH2)r in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9,10-methanoanthracen-9(10H)-yl the group -L1-N(R4)— together represents a piperidyl ring which is linked to L2
    Type: Application
    Filed: July 4, 2003
    Publication date: November 2, 2006
    Applicant: AstraZeneca AB
    Inventors: Asim Ray, Emma Evertsson, Anna Stina Linusson Jonsson, Pernilla Sandberg, Tord Ingiiardt, Anette Svensson, Kay Brickmann